BR0309825A - Método e composição farmacêutica para reduzir a dor em um mamìfero que sofra de um neoplasma - Google Patents

Método e composição farmacêutica para reduzir a dor em um mamìfero que sofra de um neoplasma

Info

Publication number
BR0309825A
BR0309825A BR0309825-7A BR0309825A BR0309825A BR 0309825 A BR0309825 A BR 0309825A BR 0309825 A BR0309825 A BR 0309825A BR 0309825 A BR0309825 A BR 0309825A
Authority
BR
Brazil
Prior art keywords
neoplasm
mammal
pharmaceutical composition
reduce pain
mammal suffering
Prior art date
Application number
BR0309825-7A
Other languages
English (en)
Inventor
Donald Morris
Matthew C Coffey
Bradley G Thompson
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Publication of BR0309825A publication Critical patent/BR0309825A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"MéTODO E COMPOSIçãO FARMACêUTICA PARA REDUZIR A DOR EM UM MAMìFERO QUE SOFRA DE UM NEOPLASMA". A presente invenção provê um método para reduzir a dor associada com neoplasmas em um mamífero, compreendendo administrar uma quantidade eficaz de um ou mais vírus oncolíticos. Preferivelmente, o mamífero também recebe um analgésico, e a quantidade de analgésico requerida pelo mamífero é reduzida quando o vírus oncolítico é administrado. O vírus oncolítico é de preferência o reovírus. O mamífero pode ser adicionalmente submetido à quimioterapia, imunoterapia, terapias hormonal e/ou de radiação.
BR0309825-7A 2002-05-09 2003-05-07 Método e composição farmacêutica para reduzir a dor em um mamìfero que sofra de um neoplasma BR0309825A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37867502P 2002-05-09 2002-05-09
US44317703P 2003-01-29 2003-01-29
PCT/CA2003/000674 WO2003094938A1 (en) 2002-05-09 2003-05-07 Method for reducing pain using oncolytic viruses

Publications (1)

Publication Number Publication Date
BR0309825A true BR0309825A (pt) 2005-03-01

Family

ID=29423642

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0309825-7A BR0309825A (pt) 2002-05-09 2003-05-07 Método e composição farmacêutica para reduzir a dor em um mamìfero que sofra de um neoplasma

Country Status (20)

Country Link
US (2) US20040091458A1 (pt)
EP (1) EP1505992B1 (pt)
JP (1) JP5241059B2 (pt)
AR (1) AR039986A1 (pt)
AT (1) ATE404213T1 (pt)
AU (1) AU2003229431B8 (pt)
BR (1) BR0309825A (pt)
CA (1) CA2484398C (pt)
DE (2) DE60322885D1 (pt)
DK (1) DK1505992T3 (pt)
ES (1) ES2239928T3 (pt)
HK (1) HK1070565A1 (pt)
IL (1) IL164695A (pt)
MX (1) MXPA04011007A (pt)
NZ (1) NZ536102A (pt)
PT (1) PT1505992E (pt)
SI (1) SI1505992T1 (pt)
TR (1) TR200501460T3 (pt)
TW (1) TWI316405B (pt)
WO (1) WO2003094938A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
WO2007099401A2 (en) 2005-08-01 2007-09-07 University Technologies International, Inc. Oncolytic attenuated reoviruses for treatment of proliferative disorders
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
WO2008144067A1 (en) * 2007-05-21 2008-11-27 Board Of Regents, University Of Texas System Methods and compositions for treatment of cancer using oncolytic rsv activity
US8450106B2 (en) * 2007-10-17 2013-05-28 The Ohio State University Research Foundation Oncolytic virus
TW200951143A (en) * 2008-05-27 2009-12-16 Oncolytics Biotech Inc Modulating interstitial pressure and oncolytic viral delivery and distribution
KR20100054358A (ko) * 2008-11-14 2010-05-25 김재은 스틱 연고
AR076540A1 (es) * 2009-05-01 2011-06-22 Eurand Inc Composiciones de comprimidos de desintegracion oral que comprenden combinaciones de analgesicos no- opioides y opioides, forma de dosificacion. metodo de preparacion. metodo para tratar dolor
EP2383577A1 (en) * 2010-04-30 2011-11-02 Deutsches Krebsforschungszentrum Diagnostic method for predicting the response of a patient to chemovirotherapy or radiovirotherapy
KR20180021083A (ko) 2015-06-19 2018-02-28 신라젠(주) 바이러스성 색전술을 위한 조성물 및 방법
CA3018307A1 (en) 2016-02-16 2017-08-24 Osaka University Pharmaceutical composition for use in treating fibrosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
NZ518945A (en) * 1997-10-09 2007-03-30 Wellstat Biologics Corp Treatment of neoplasms with viruses
US6428968B1 (en) * 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
TWI289158B (en) * 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus

Also Published As

Publication number Publication date
EP1505992A1 (en) 2005-02-16
DE03722131T1 (de) 2005-09-15
CA2484398C (en) 2014-01-21
CA2484398A1 (en) 2003-11-20
PT1505992E (pt) 2008-10-06
DK1505992T3 (da) 2008-10-06
ES2239928T3 (es) 2009-02-16
TW200402305A (en) 2004-02-16
IL164695A0 (en) 2005-12-18
ATE404213T1 (de) 2008-08-15
TR200501460T3 (tr) 2005-06-21
DE60322885D1 (de) 2008-09-25
AR039986A1 (es) 2005-03-09
IL164695A (en) 2010-12-30
US20080081032A1 (en) 2008-04-03
WO2003094938A1 (en) 2003-11-20
EP1505992B1 (en) 2008-08-13
MXPA04011007A (es) 2005-02-14
AU2003229431A1 (en) 2003-11-11
TWI316405B (en) 2009-11-01
NZ536102A (en) 2008-01-31
AU2003229431B2 (en) 2008-01-17
AU2003229431B8 (en) 2009-07-02
SI1505992T1 (sl) 2009-02-28
HK1070565A1 (en) 2005-06-24
ES2239928T1 (es) 2005-10-16
US20040091458A1 (en) 2004-05-13
JP2005526124A (ja) 2005-09-02
JP5241059B2 (ja) 2013-07-17

Similar Documents

Publication Publication Date Title
Dekhuijzen Antioxidant properties of N‐acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease
Malaviya Landmark papers on the discovery of methotrexate for the treatment of rheumatoid arthritis and other systemic inflammatory rheumatic diseases: a fascinating story
BR0309825A (pt) Método e composição farmacêutica para reduzir a dor em um mamìfero que sofra de um neoplasma
BR9908030A (pt) Composição farmacêutica compreendendo uma ou mais unidades de dose oralmente ministráveis, e, processos para prepará-la, para uso da mesma, e para tratar uma condição ou distúrbio médico em um indivìduo em que tratamento com um inibidor da ciclooxigenase-2 é indicado
BRPI0414435A (pt) métodos e reagentes para o tratamento de distúrbios imunoinflamatórios
BR0314943A (pt) Inibidores da proteìna reguladora da condutância transmembrana da fibrose cìstica e usos destes
BR0009647A (pt) Docetaxel em combinação com rhumab her2 para o tratamento de cânceres
BR0013122A (pt) Ciclobenzaprina para tratamento de distúrbio de ansiedade generalizado e composições de ciclobenzaprina
BRPI0516531A (pt) imunoterapia de distúrbios auto-imunes
Gómez‐Ramírez et al. Short‐term perioperative iron in major orthopedic surgery: state of the art
BR0316685A (pt) Composições e métodos para a administração aperfeiçoada por via mucosal de peptìdeos fixadores ao receptor de y2 e métodos para tratar e prevenir a obesidade
BR112019005133A2 (pt) composição farmacêutica, recipiente vedado, inalador de dose medida, e, métodos para tratar um paciente sofrendo ou susceptível de sofrer de um distúrbio respiratório, para melhorar a estabilidade de uma composição farmacêutica, para melhoria do desempenho de dispersão em aerossol de uma composição farmacêutica e para reduzir o potencial de aquecimento global de uma composição farmacêutica.
BRPI0317463B8 (pt) composto, composição farmacêutica compreendendo o mesmo e uso do referido composto no preparo de um medicamento para tratar uma doença amilóide de transtiretina
BR0209689A (pt) Uso de fragmento de hmg como agente anti-inflamatório
BR0306444A (pt) Uso de anticorpos anti-tnf(alfa) e outra droga
BRPI0408902A (pt) composições de inibidores seletivos da ciclooxigenase-2 e agonistas de 5-ht 1b/1d para o tratamento e a prevenção de enxaqueca
BR9914901A (pt) Agonistas do receptor 5ht1 e metoclopramida para o tratamento de enxaqueca
BRPI0507657A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
AR040709A1 (es) Formulacion de lamotrigina de liberacion prolongada y uso de la misma para su preparacion
BR9908510A (pt) Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana
Routray et al. Comparison of pregabalin with gabapentin as preemptive analgesic in lumbar spine surgery
BR0317573A (pt) Agentes de receptores de linfotoxina beta em combinação com agentes quimioterapêuticos
Majumdar et al. Intravenous paracetamol infusion: Superior pain management and earlier discharge from hospital in patients undergoing palliative head-neck cancer surgery
BR0313470A (pt) Combinações terapêuticas de inibidores erbb quinase e terapias antineoplásicas
AR053928A1 (es) Metodos reactivos para el tratamiento de trastornos inflamatorios

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 7A, 8A E 9A ANUIDADES.